Inclusion Criteria:  Patient enrolled in a PACE organization during the implementation period; and, PACE organization contractually receiving pharmacy services from CareKinesis Patient prescribed a CYP2D6 activated opioid, namely codeine, hydrocodone, oxycodone and/or tramadol Patients with chronic non-cancer pain (CNCP) Patient's prescriber orders a PGx test based upon his/her determination that the patient could potentially benefit from PGx testing Patient is able to read, understand, and provide informed consent to participate  Exclusion Criteria:  Patient prescribed an opioid that is not metabolized by CYP2D6 including, but not limited to, oxymorphone, morphine, hydromorphone Have taken an investigational product in the last 30 days Current use of illicit substances Immediate family members of site staff, or site staff may not be enrolled in the study without first obtaining IRB authorization Any other medical, cognitive or physical abnormality, disease, or disorder that would prohibit the patient from completing study procedures in the judgement of the investigator